Citadel Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.76M Sell
120,045
-567,043
-83% -$17.7M ﹤0.01% 2165
2025
Q1
$23.1M Buy
687,088
+359,785
+110% +$12.1M ﹤0.01% 819
2024
Q4
$12.8M Sell
327,303
-395,201
-55% -$15.5M ﹤0.01% 1173
2024
Q3
$28.4M Sell
722,504
-46,222
-6% -$1.82M 0.01% 705
2024
Q2
$30M Sell
768,726
-518,349
-40% -$20.2M 0.01% 684
2024
Q1
$55.4M Buy
1,287,075
+20,231
+2% +$871K 0.01% 448
2023
Q4
$58.4M Buy
1,266,844
+543,320
+75% +$25M 0.01% 415
2023
Q3
$24.7M Buy
723,524
+222,512
+44% +$7.6M 0.01% 697
2023
Q2
$19.3M Sell
501,012
-370,222
-42% -$14.3M ﹤0.01% 837
2023
Q1
$31.2M Sell
871,234
-293,173
-25% -$10.5M 0.01% 646
2022
Q4
$45.9M Buy
1,164,407
+22,405
+2% +$883K 0.01% 473
2022
Q3
$41.2M Sell
1,142,002
-506,037
-31% -$18.3M 0.01% 476
2022
Q2
$50.1M Buy
1,648,039
+206,959
+14% +$6.3M 0.01% 376
2022
Q1
$44.1M Buy
1,441,080
+153,277
+12% +$4.69M 0.01% 486
2021
Q4
$40.2M Buy
1,287,803
+446,587
+53% +$14M 0.01% 579
2021
Q3
$12.9M Sell
841,216
-202,327
-19% -$3.09M ﹤0.01% 1205
2021
Q2
$19.4M Buy
1,043,543
+820,991
+369% +$15.3M ﹤0.01% 970
2021
Q1
$3.98M Buy
222,552
+151,002
+211% +$2.7M ﹤0.01% 2370
2020
Q4
$1.1M Sell
71,550
-240,132
-77% -$3.7M ﹤0.01% 3161
2020
Q3
$3.45M Sell
311,682
-78,578
-20% -$870K ﹤0.01% 1783
2020
Q2
$4.89M Sell
390,260
-115,769
-23% -$1.45M ﹤0.01% 1525
2020
Q1
$5.74M Buy
506,029
+273,764
+118% +$3.1M ﹤0.01% 1360
2019
Q4
$3.05M Sell
232,265
-39,820
-15% -$522K ﹤0.01% 2006
2019
Q3
$2.45M Sell
272,085
-165,495
-38% -$1.49M ﹤0.01% 2207
2019
Q2
$4.32M Sell
437,580
-214,443
-33% -$2.11M ﹤0.01% 1772
2019
Q1
$6.63M Sell
652,023
-186,279
-22% -$1.89M ﹤0.01% 1386
2018
Q4
$5.29M Buy
838,302
+84,367
+11% +$532K ﹤0.01% 1410
2018
Q3
$9.95M Buy
+753,935
New +$9.95M ﹤0.01% 1101